Enovis Corporation (NYSE:ENOV) Receives $44.50 Average Target Price from Brokerages

Shares of Enovis Corporation (NYSE:ENOV) have been assigned an average recommendation of “Moderate Buy” from the nine research firms that are presently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have given a buy rating to the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $44.50.

Several research analysts have issued reports on ENOV shares. Weiss Ratings restated a “sell (e+)” rating on shares of Enovis in a research report on Friday, April 10th. William Blair started coverage on Enovis in a research report on Friday, April 17th. They set an “outperform” rating for the company. Evercore restated an “outperform” rating and set a $36.00 target price on shares of Enovis in a research report on Friday, May 8th. BTIG Research restated a “buy” rating and set a $39.00 target price on shares of Enovis in a research report on Friday, May 22nd. Finally, Zacks Research lowered Enovis from a “strong-buy” rating to a “hold” rating in a report on Monday, June 1st.

Institutional Investors Weigh In On Enovis

Hedge funds have recently made changes to their positions in the company. Arax Advisory Partners purchased a new stake in shares of Enovis in the 4th quarter worth $29,000. EverSource Wealth Advisors LLC lifted its holdings in shares of Enovis by 125.4% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company’s stock worth $40,000 after buying an additional 707 shares during the period. GAMMA Investing LLC lifted its holdings in shares of Enovis by 353.5% in the 4th quarter. GAMMA Investing LLC now owns 1,855 shares of the company’s stock worth $49,000 after buying an additional 1,446 shares during the period. Atlantic Union Bankshares Corp purchased a new stake in shares of Enovis in the 3rd quarter worth $64,000. Finally, Danske Bank A S purchased a new stake in shares of Enovis in the 3rd quarter worth $64,000. 98.45% of the stock is currently owned by hedge funds and other institutional investors.

Enovis Stock Down 0.5%

Shares of NYSE:ENOV opened at $23.65 on Thursday. Enovis has a 1 year low of $20.82 and a 1 year high of $36.82. The business has a 50 day simple moving average of $24.05 and a two-hundred day simple moving average of $24.74. The firm has a market capitalization of $1.36 billion, a PE ratio of -1.19 and a beta of 1.38. The company has a debt-to-equity ratio of 0.87, a current ratio of 2.04 and a quick ratio of 1.05.

Enovis (NYSE:ENOV) last announced its earnings results on Thursday, May 7th. The company reported $0.89 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.82 by $0.07. Enovis had a positive return on equity of 10.32% and a negative net margin of 49.92%.The business had revenue of $589.15 million during the quarter, compared to analyst estimates of $572.02 million. During the same quarter in the previous year, the business earned $0.81 earnings per share. The company’s revenue for the quarter was up 5.4% compared to the same quarter last year. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. On average, equities analysts predict that Enovis will post 3.65 EPS for the current year.

Enovis Company Profile

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.